These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

572 related items for PubMed ID: 30251059

  • 1. The effect of extra-articular manifestations on tumor necrosis factor-α inhibitor treatment duration in patients with ankylosing spondylitis: nationwide data from the Korean College of Rheumatology BIOlogics (KOBIO) registry.
    Kim Y, Park S, Kim HS.
    Clin Rheumatol; 2018 Dec; 37(12):3275-3284. PubMed ID: 30251059
    [Abstract] [Full Text] [Related]

  • 2. Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry.
    Favalli EG, Pregnolato F, Biggioggero M, Becciolini A, Penatti AE, Marchesoni A, Meroni PL.
    Arthritis Care Res (Hoboken); 2016 Apr; 68(4):432-9. PubMed ID: 26556048
    [Abstract] [Full Text] [Related]

  • 3. Drug survival of tumor necrosis factor α inhibitors in patients with ankylosing spondylitis in Korea.
    Jeong H, Eun YH, Kim IY, Kim H, Ahn JK, Lee J, Koh EM, Cha HS.
    Korean J Intern Med; 2018 Mar; 33(2):407-416. PubMed ID: 27729625
    [Abstract] [Full Text] [Related]

  • 4. Predictors of extra-articular manifestations in axial spondyloarthritis and their influence on TNF-inhibitor prescribing patterns: results from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis.
    Derakhshan MH, Dean L, Jones GT, Siebert S, Gaffney K.
    RMD Open; 2020 Jul; 6(2):. PubMed ID: 32641447
    [Abstract] [Full Text] [Related]

  • 5. Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.
    Favalli EG, Sinigaglia L, Becciolini A, Grosso V, Gorla R, Bazzani C, Atzeni F, Sarzi Puttini PC, Fusaro E, Pellerito R, Caporali R.
    Int J Rheum Dis; 2018 Feb; 21(2):422-430. PubMed ID: 29082659
    [Abstract] [Full Text] [Related]

  • 6. Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register.
    Lie E, Lindström U, Zverkova-Sandström T, Olsen IC, Forsblad-d'Elia H, Askling J, Kapetanovic MC, Kristensen LE, Jacobsson LTH.
    Ann Rheum Dis; 2017 Sep; 76(9):1515-1521. PubMed ID: 28254789
    [Abstract] [Full Text] [Related]

  • 7. Effects of tapering tumor necrosis factor inhibitor on the achievement of inactive disease in patients with axial spondyloarthritis: a nationwide cohort study.
    Park JW, Kim HA, Shin K, Park YB, Kim TH, Song YW, Lee EY.
    Arthritis Res Ther; 2019 Jul 04; 21(1):163. PubMed ID: 31272498
    [Abstract] [Full Text] [Related]

  • 8. TNF-alpha inhibitors for ankylosing spondylitis.
    Maxwell LJ, Zochling J, Boonen A, Singh JA, Veras MM, Tanjong Ghogomu E, Benkhalti Jandu M, Tugwell P, Wells GA.
    Cochrane Database Syst Rev; 2015 Apr 18; 2015(4):CD005468. PubMed ID: 25887212
    [Abstract] [Full Text] [Related]

  • 9. Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis: Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry.
    Glintborg B, Sørensen IJ, Østergaard M, Dreyer L, Mohamoud AA, Krogh NS, Hendricks O, Andersen LS, Raun JL, Kowalski MR, Danielsen L, Pelck R, Nordin H, Pedersen JK, Kraus DG, Christensen SR, Hansen IM, Esbesen J, Schlemmer A, Loft AG, Al Chaer N, Salomonsen L, Hetland ML.
    J Rheumatol; 2017 Jan 18; 44(1):59-69. PubMed ID: 27909080
    [Abstract] [Full Text] [Related]

  • 10. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
    Favalli EG, Pontikaki I, Becciolini A, Biggioggero M, Ughi N, Romano M, Crotti C, Gattinara M, Gerloni V, Marchesoni A, Meroni PL.
    Clin Rheumatol; 2017 Aug 18; 36(8):1747-1755. PubMed ID: 28597133
    [Abstract] [Full Text] [Related]

  • 11. Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database.
    Wendling D, Joshi A, Reilly P, Jalundhwala YJ, Mittal M, Bao Y.
    Curr Med Res Opin; 2014 Dec 18; 30(12):2515-21. PubMed ID: 25252590
    [Abstract] [Full Text] [Related]

  • 12. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study.
    Arends S, Brouwer E, van der Veer E, Groen H, Leijsma MK, Houtman PM, Th A Jansen TL, Kallenberg CG, Spoorenberg A.
    Arthritis Res Ther; 2011 Jun 20; 13(3):R94. PubMed ID: 21689401
    [Abstract] [Full Text] [Related]

  • 13. The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study.
    Lie E, Kristensen LE, Forsblad-d'Elia H, Zverkova-Sandström T, Askling J, Jacobsson LT, ARTIS Study Group.
    Ann Rheum Dis; 2015 Jun 20; 74(6):970-8. PubMed ID: 25710471
    [Abstract] [Full Text] [Related]

  • 14. Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry.
    Glintborg B, Østergaard M, Krogh NS, Tarp U, Manilo N, Loft AG, Hansen A, Schlemmer A, Fana V, Lindegaard HM, Nordin H, Rasmussen C, Ejstrup L, Jensen DV, Petersen PM, Hetland ML.
    Ann Rheum Dis; 2013 Jul 20; 72(7):1149-55. PubMed ID: 22941767
    [Abstract] [Full Text] [Related]

  • 15. The Effect of Tumor Necrosis Factor-Alpha Inhibitors on Uveitis in Patients with Ankylosing Spondylitis.
    Lee S, Park YJ, Lee JY.
    J Korean Med Sci; 2019 Nov 04; 34(42):e278. PubMed ID: 31674159
    [Abstract] [Full Text] [Related]

  • 16. Comparative Analysis and Predictors of 10-year Tumor Necrosis Factor Inhibitors Drug Survival in Patients with Spondyloarthritis: First-year Response Predicts Longterm Drug Persistence.
    Flouri ID, Markatseli TE, Boki KA, Papadopoulos I, Skopouli FN, Voulgari PV, Settas L, Zisopoulos D, Iliopoulos A, Geborek P, Drosos AA, Boumpas DT, Sidiropoulos P.
    J Rheumatol; 2018 Jun 04; 45(6):785-794. PubMed ID: 29606666
    [Abstract] [Full Text] [Related]

  • 17. The effectiveness of a real life dose reduction strategy for tumour necrosis factor inhibitors in ankylosing spondylitis and psoriatic arthritis.
    Fong W, Holroyd C, Davidson B, Armstrong R, Harvey N, Dennison E, Cooper C, Edwards CJ.
    Rheumatology (Oxford); 2016 Oct 04; 55(10):1837-42. PubMed ID: 27354684
    [Abstract] [Full Text] [Related]

  • 18. Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey.
    Lopalco G, Venerito V, Cantarini L, Emmi G, Salaffi F, Di Carlo M, Tafuri S, Gentileschi S, Di Scala G, Nivuori M, Cacciapaglia F, Galeazzi M, Lapadula G, Iannone F.
    Clin Exp Rheumatol; 2019 Oct 04; 37(5):762-767. PubMed ID: 31025925
    [Abstract] [Full Text] [Related]

  • 19. Risk of active tuberculosis in patients with inflammatory arthritis receiving TNF inhibitors: a look beyond the baseline tuberculosis screening protocol.
    Soare A, Gheorghiu AM, Aramă V, Bumbăcea D, Dobrotă R, Oneaţă R, Pintilie S, Milicescu M, Ancuţa I, Martin A, Sasu M, Ciofu C, Macovei L, Stoica V, Bojincă M, Mihai C.
    Clin Rheumatol; 2018 Sep 04; 37(9):2391-2397. PubMed ID: 29150737
    [Abstract] [Full Text] [Related]

  • 20. One-Year Treatment Outcomes of Secukinumab Versus Tumor Necrosis Factor Inhibitors in Spondyloarthritis: Results From Five Nordic Biologic Registries Including More Than 10,000 Treatment Courses.
    Glintborg B, Lindström U, Giuseppe DD, Provan SA, Gudbjornsson B, Hetland ML, Michelsen B, Wallman JK, Aaltonen K, Hokkanen AM, Nordström D, Jørgensen TS, Hansen RL, Geirsson AJ, Grøn KL, Krogh NS, Askling J, Kristensen LE, Jacobsson LTH, Danish Rheumatology Database (DANBIO), Anti-Rheumatic Therapy in Sweden/Swedish Rheumatology Quality (ARTIS/SRQ), Center for Rheumatology Research (ICEBIO), Finnish Register of Biological Treatment (ROB-FIN), and Norwegian Antirheumatic Drug Register (NOR-DMARD) registries.
    Arthritis Care Res (Hoboken); 2022 May 04; 74(5):748-758. PubMed ID: 33253491
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.